CHRS
Price
$1.01
Change
-$0.10 (-9.01%)
Updated
Apr 24 closing price
Capitalization
117.06M
13 days until earnings call
DERM
Price
$7.56
Change
+$0.08 (+1.07%)
Updated
Apr 24 closing price
Capitalization
73.35M
18 days until earnings call
Ad is loading...

CHRS vs DERM

Header iconCHRS vs DERM Comparison
Open Charts CHRS vs DERMBanner chart's image
Coherus BioSciences
Price$1.01
Change-$0.10 (-9.01%)
Volume$2.1M
Capitalization117.06M
Journey Medical
Price$7.56
Change+$0.08 (+1.07%)
Volume$113.37K
Capitalization73.35M
CHRS vs DERM Comparison Chart
Loading...
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DERM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CHRS vs. DERM commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHRS is a Buy and DERM is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (CHRS: $1.01 vs. DERM: $7.56)
Brand notoriety: CHRS: Not notable vs. DERM: Notable
CHRS represents the Biotechnology, while DERM is part of the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: CHRS: 109% vs. DERM: 142%
Market capitalization -- CHRS: $117.06M vs. DERM: $73.35M
CHRS [@Biotechnology] is valued at $117.06M. DERM’s [@Pharmaceuticals: Other] market capitalization is $73.35M. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Biotechnology] industry is $2.16B. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHRS’s FA Score shows that 0 FA rating(s) are green whileDERM’s FA Score has 0 green FA rating(s).

  • CHRS’s FA Score: 0 green, 5 red.
  • DERM’s FA Score: 0 green, 5 red.
According to our system of comparison, both CHRS and DERM are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHRS’s TA Score shows that 5 TA indicator(s) are bullish while DERM’s TA Score has 5 bullish TA indicator(s).

  • CHRS’s TA Score: 5 bullish, 4 bearish.
  • DERM’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both CHRS and DERM are a good buy in the short-term.

Price Growth

CHRS (@Biotechnology) experienced а -9.82% price change this week, while DERM (@Pharmaceuticals: Other) price change was +20.96% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.06%. For the same industry, the average monthly price growth was -5.30%, and the average quarterly price growth was -11.62%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +4.30%. For the same industry, the average monthly price growth was -2.30%, and the average quarterly price growth was -8.27%.

Reported Earning Dates

CHRS is expected to report earnings on Jul 31, 2025.

DERM is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+8.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Pharmaceuticals: Other (+4.30% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CHRS($117M) has a higher market cap than DERM($73.4M). DERM YTD gains are higher at: 93.350 vs. CHRS (-26.812). CHRS has higher annual earnings (EBITDA): 37.3M vs. DERM (-5.69M). CHRS has more cash in the bank: 97.7M vs. DERM (24.7M). DERM has less debt than CHRS: DERM (131K) vs CHRS (270M). CHRS has higher revenues than DERM: CHRS (304M) vs DERM (79.9M).
CHRSDERMCHRS / DERM
Capitalization117M73.4M159%
EBITDA37.3M-5.69M-656%
Gain YTD-26.81293.350-29%
P/E Ratio4.04N/A-
Revenue304M79.9M380%
Total Cash97.7M24.7M396%
Total Debt270M131K206,107%
FUNDAMENTALS RATINGS
CHRS vs DERM: Fundamental Ratings
CHRS
DERM
OUTLOOK RATING
1..100
1928
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
71
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
4635
P/E GROWTH RATING
1..100
4940
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DERM's Valuation (71) in the Biotechnology industry is in the same range as CHRS (90). This means that DERM’s stock grew similarly to CHRS’s over the last 12 months.

DERM's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CHRS (100). This means that DERM’s stock grew similarly to CHRS’s over the last 12 months.

DERM's SMR Rating (96) in the Biotechnology industry is in the same range as CHRS (100). This means that DERM’s stock grew similarly to CHRS’s over the last 12 months.

DERM's Price Growth Rating (35) in the Biotechnology industry is in the same range as CHRS (46). This means that DERM’s stock grew similarly to CHRS’s over the last 12 months.

DERM's P/E Growth Rating (40) in the Biotechnology industry is in the same range as CHRS (49). This means that DERM’s stock grew similarly to CHRS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CHRSDERM
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
84%
Momentum
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
89%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
71%
Bullish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 3 days ago
72%
Bullish Trend 1 day ago
88%
Declines
ODDS (%)
Bearish Trend 22 days ago
86%
Bearish Trend 15 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
87%
Aroon
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DERM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GOTRF1.240.10
+9.11%
Goliath Resources Ltd.
ASMVY19.410.34
+1.76%
ASMPT LTD.
NPNYY6.660.06
+0.91%
Nippon Yusen Kabushiki Kaisha
TRSSX22.56N/A
N/A
T. Rowe Price Instl Small-Cap Stock
EVSRX22.06N/A
N/A
Allspring Disciplined US Core R6

CHRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CHRS has been loosely correlated with ADCT. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if CHRS jumps, then ADCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHRS
1D Price
Change %
CHRS100%
-9.01%
ADCT - CHRS
39%
Loosely correlated
+5.43%
ARRY - CHRS
39%
Loosely correlated
+5.31%
AXON - CHRS
38%
Loosely correlated
+2.39%
XENE - CHRS
35%
Loosely correlated
+1.62%
AMRN - CHRS
35%
Loosely correlated
+7.92%
More

DERM and

Correlation & Price change

A.I.dvisor tells us that DERM and CRDL have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DERM and CRDL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DERM
1D Price
Change %
DERM100%
+1.07%
CRDL - DERM
27%
Poorly correlated
-0.93%
CHRS - DERM
27%
Poorly correlated
-9.01%
AQST - DERM
25%
Poorly correlated
+1.06%
VXRT - DERM
24%
Poorly correlated
+4.74%
DRMA - DERM
22%
Poorly correlated
-5.35%
More